1420 ET - Hims & Hers Health appears to have two potential strategies with a range of full-year revenue outcomes, Bank of America analysts say in a research note. If Hims grows its personalized semaglutide business, it could meet or beat the top end of its guidance, generating over $900 million in GLP-1 revenue, the analysts estimated. Such a strategy could reintroduce litigation risk, though, they added. Alternatively, if Hims reinvests more in its core business, the segment's trends could stabilize or accelerate though overall revenue could fall toward the low end of guidance, they said. If the company pursues both at the same time, it could outperform the analysts' estimates for $2.32 billion in full-year sales, they said. (kelly.cloonan@wsj.com)
(END) Dow Jones Newswires
May 06, 2025 14:30 ET (18:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。